Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

Core Insights - Harmony Biosciences' experimental drug for a rare genetic disorder did not achieve its primary endpoint in a late-stage clinical trial, leading to an 8% decline in the company's shares before market opening [1] Company Summary - The failure of the drug in the late-stage trial has significant implications for Harmony Biosciences, affecting investor confidence and market valuation [1]